|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2400083139 |
|
最近更新日期: Date of Last Refreshed on: |
2024-04-16 16:32:05 |
|
注册时间: Date of Registration: |
2024-04-16 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
甘油二酯食用油降血脂降尿酸减重评价项目 |
|
Public title: |
Evaluation of diglycerides in edible oil for lowering blood lipids, uric acid and weight loss |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
甘油二酯食用油降血脂降尿酸减重评价项目 |
|
Scientific title: |
Evaluation of diglycerides in edible oil for lowering blood lipids, uric acid and weight loss |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
阿不都沙拉木·阿不都外力 |
研究负责人: |
闫媛媛 |
|
Applicant: |
Abudushalamu Abuduwaili |
Study leader: |
Yuanyuan Yan |
|
申请注册联系人电话: Applicant telephone: |
+86 132 1638 0106 |
研究负责人电话:
Study leader's |
+86 183 2197 0015 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
1262688432@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
yanyuanyuan0801@outlook.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
上海市黄浦区重庆南路227号 |
研究负责人通讯地址: |
上海市黄浦区重庆南路227号 |
|
Applicant address: |
No. 227, Chongqing South Road, Huangpu District, Shanghai |
Study leader's address: |
No. 227, Chongqing South Road, Huangpu District, Shanghai |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
上海交通大学医学院 |
||
|
Applicant's institution: |
Shanghai Jiao Tong University School of Medicine |
||
|
研究负责人所在单位: |
上海交通大学医学院 |
||
|
Affiliation of the Leader: |
Shanghai Jiao Tong University School of Medicine |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
SJUPN-2024-002-KS1-KS2 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
上海交通大学医学院公共卫生及护理科研伦理委员会 |
||
|
Name of the ethic committee: |
Joint Research Ethics Board of the Shanghai Jiao Tong University Schools of Public Health and Nursing |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-04-01 00:00:00 | ||
|
伦理委员会联系人: |
王慧 |
||
|
Contact Name of the ethic committee: |
Wang Hui |
||
|
伦理委员会联系地址: |
上海市黄浦区重庆南路227号 |
||
|
Contact Address of the ethic committee: |
227 Chongqing Road South, Huangpu District, Shanghai, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 134 0210 3168 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
上海交通大学医学院 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Primary sponsor: |
Shanghai Jiao Tong University School of Medicine |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
上海市黄浦区重庆南路227号 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Primary sponsor's address: |
No. 227, Chongqing South Road, Huangpu District, Shanghai |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
经费或物资来源: |
上海交通大学医学院和江南大学 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Source(s) of funding: |
Shanghai Jiao Tong University School of Medicine and Jiangnan University |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
研究疾病: |
高尿酸血症 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Target disease: |
Hyperuricemia |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
研究目的: |
本研究旨在评估和比较膳食补充甘油二酯对高尿酸血症和痛风人群的血尿酸和其他血脂指标、体重的影响,从而降低尿酸含量,促进人群健康,为进一步完善高尿酸血症和痛风人群食养工作提供理论基础。 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Objectives of Study: |
The purpose of this study was to evaluate and compare the effects of dietary diglyceride supplementation on blood uric acid and other blood lipid indexes and body weight in people with hyperuricemia and gout, so as to reduce uric acid content and promote population health, and provide a theoretical basis for further improving the dietary and nutritional work of people with hyperuricemia and gout. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
纳入标准: |
(1)25岁≤年龄≤50岁,男女比例:2:1, BMI>18kg/m2人群(剔除偏瘦人群); (2)符合无症状高尿酸血症的诊断标准;无症状高尿酸血症指患者仅有高尿酸血症(血尿酸=450-540μmol/L),或者(血尿酸=450-480μmol/L)合并高血压、脂代谢异常、糖尿病、肥胖、脑卒中、冠心病、心功能不全、尿酸性肾石病、肾功能损害(≥CKD2期)等,而无关节炎、痛风石、尿酸结石等临床症状。 (3)饮食状态良好,日常无吸烟(每天被动或者主动吸烟不超过1小时)、无饮酒(每周饮酒低于14次)、无大量节食现象; (4)确保本实验期间不食用其他影响代谢药物。每周居家饮食至少5次,每天摄入25g食用油; (5)能够按临床试验要求,遵守规定; (6)受试者或监护人已签署知情同意书; (7)患者填写书面知情同意书和食物频率调查表,并在整个试验期间承诺配合研究。 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Inclusion criteria |
(1) 25 years old≤ age ≤ 50 years old, male-to-female ratio: 2:1, BMI>18kg/m2 (excluding thin people); (2) meet the diagnostic criteria for asymptomatic hyperuricemia; Asymptomatic hyperuricemia refers to patients with only hyperuricemia (blood uric acid = 450-540 μmol/L), or (blood uric acid = 450-480 μmol/L) combined with hypertension, dyslipidemia, diabetes, obesity, stroke, coronary heart disease, cardiac insufficiency, uric acid nephrolithiasis, renal impairment (≥ CKD2 stage), etc., but no clinical symptoms such as arthritis, tophi, uric acid stones, etc. (3) Good diet, no daily smoking (passive or active smoking no more than 1 hour a day), no alcohol (less than 14 times a week), no heavy dieting; (4) Ensure that other drugs that affect metabolism are not consumed during this experiment. Eat at home at least 5 times a week, and consume 25g of cooking oil per day; (5) Be able to comply with the requirements of clinical trials; (6) The subject or guardian has signed the informed consent form; (7) The patient fills in the written informed consent form and the food frequency questionnaire and undertakes to cooperate with the study throughout the trial period. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
排除标准: |
有下列情况者不入选: (1)在过去6个月内无长期服用影响脂代谢相关药物情况; (2)过去6个月内滥用麻醉品、精神药物和卷烟; (3)在研究期间或过去2个月内,每周至少两次补充营养素,如益生菌、多种矿物质、综合维生素等; (4)过去6个月内体重迅速减轻,全胃肠外营养和蛋白质营养不良; (5)孕妇或哺乳期妇女,或未来6个月有怀孕计划; (6)患者依从性较差,随访可能性差; |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Exclusion criteria: |
Those who have the following conditions will not be selected: (1) No long-term use of drugs related to lipid metabolism in the past 6 months; (2) Abuse of narcotics, psychotropic substances and cigarettes in the past 6 months; (3) Supplement nutrients, such as probiotics, multi-minerals, multivitamins, etc., at least twice a week during the study period or in the past 2 months; (4) rapid weight loss in the past 6 months, total parenteral nutrition and protein malnutrition; (5) Pregnant or lactating women, or those who plan to become pregnant in the next 6 months; (6) poor compliance and poor follow-up possibility; |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2024-04-16 00:00:00至 To 2024-09-30 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2024-04-16 00:00:00 至 To 2024-09-30 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
采用分层随机方法,在性别、年龄、BMI分层基础上研究单位按受试者的就诊顺序分三次发给相应编号的产品,不得随意更改编号排序。运用SPSS 22.0统计软件,按病例数及随机比例分成随机数字分组表。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
The stratified randomization method is adopted, and on the basis of gender, age, and BMI stratification, the research unit will issue the corresponding numbered products in three times according to the order of the subjects' visits, and the numbered order shall not be changed at will. SPSS 22.0 statistical software was used to divide the number of cases into random number grouping tables according to the number of cases and random proportions |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
双盲 |
|
Blinding: |
Double-blinded |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
否 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
none |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病历记录表 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
CRF |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |